JP2019521105A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521105A5
JP2019521105A5 JP2018563888A JP2018563888A JP2019521105A5 JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5 JP 2018563888 A JP2018563888 A JP 2018563888A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
antibody
polymorphism
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521105A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053245 external-priority patent/WO2017212375A1/en
Publication of JP2019521105A publication Critical patent/JP2019521105A/ja
Publication of JP2019521105A5 publication Critical patent/JP2019521105A5/ja
Pending legal-status Critical Current

Links

JP2018563888A 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 Pending JP2019521105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346683P 2016-06-07 2016-06-07
US62/346,683 2016-06-07
PCT/IB2017/053245 WO2017212375A1 (en) 2016-06-07 2017-06-01 Anti-c5 antibody for treating patients with complement c5 polymorphism

Publications (2)

Publication Number Publication Date
JP2019521105A JP2019521105A (ja) 2019-07-25
JP2019521105A5 true JP2019521105A5 (enExample) 2020-07-09

Family

ID=59078125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563888A Pending JP2019521105A (ja) 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体

Country Status (5)

Country Link
US (1) US20190225678A1 (enExample)
EP (1) EP3464351A1 (enExample)
JP (1) JP2019521105A (enExample)
CN (1) CN109328197A (enExample)
WO (1) WO2017212375A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
CN120571008A (zh) 2017-12-13 2025-09-02 瑞泽恩制药公司 抗c5抗体组合及其用途
PH12022550167A1 (en) 2019-08-16 2023-05-08 Regeneron Pharma High concentration anti-c5 formulations
JP7798763B2 (ja) * 2019-10-25 2026-01-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５関連疾患の治療または予防のための投与レジメン
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
HUE061548T2 (hu) * 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
EA028899B1 (ru) * 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
EP2975055A4 (en) * 2013-01-31 2016-11-02 Univ Seoul Nat R & Db Found C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2018511557A (ja) * 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法

Similar Documents

Publication Publication Date Title
JP2019521105A5 (enExample)
Wieszczycka et al. Lanthanides and tissue engineering strategies for bone regeneration
Leyhe et al. Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study
JP2019511222A5 (enExample)
TWI843040B (zh) 抗N3pGlu類澱粉β抗體及其用途
JP2017518316A5 (enExample)
BR112019007453A2 (pt) organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina
RU2016151179A (ru) Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента
Tent et al. Midfacial fractures: A retrospective etiological study over a 10-year period in Western Romanian population
JP2019528285A5 (enExample)
Battaglia et al. Guillain-Barré syndrome following severe head trauma and spine surgery
Fatima et al. Amyloid-β clearance with monoclonal antibodies: transforming Alzheimer’s treatment
Du et al. The ageing immune system as a potential target of senolytics
HK1248534A1 (zh) 周围神经的igg刺激髓鞘再生
Sarbaz et al. Medical and Surgical Complications in Three Tertiary Hospitals in the Northeast of Iran: A Multicenter Study.
Ong et al. Thrombotic paradox: ischaemic stroke in immune thrombocytopaenia. A case report and review
EP3632447A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
JP2015522601A5 (enExample)
KR20230145401A (ko) 항-N3pGlu 아밀로이드 베타 항체 및 그의 용도
Stevelink et al. Epilepsy surgery in patients with genetic refractory epilepsy: A systematic review
Berg et al. Peripheral neuropathies: corticosteroids and antivirals in Bell palsy
Natalia et al. COSTS FOR REVERSE HEMOSTATIC THERAPY OF INTERNAL CEREBRAL BLEEDING WITH THE USE OF PROTHROMBIN COMPLEX CONCENTRATE
Olupot-Olupot et al. Effects of hydroxyurea treatment on malaria infections in Sub-Saharan Africa
Ahmad et al. AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions.
Monje et al. DI-022 Real life effectiveness and safety of lenalidomide in the treatment of multiple myeloma